Alzchem Group AG

ACT

Equity

ISIN DE000A2YNT30 / Valor 48678352

Xetra (2025-03-14)

EUR 100.00+10.9%

Alzchem Group AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Alzchem Group AG is a diversified chemical manufacturer with a strong presence in the Southeast Bavarian chemical triangle and an additional production site in Sundsvall, Sweden. The company extends its global reach through sales companies located in Atlanta (USA), Shanghai (China), and Coventry (England). Alzchem is engaged in the development and production of specialty chemicals and advanced materials, catering to a wide range of industries. Its product portfolio includes high-quality guanidine salts, which are critical in the extraction of DNA and RNA for molecular diagnostics, including Covid-19 PCR test kits. The company also plays a significant role in the thermoset industry, participating in forums such as the TRFA Annual Meeting to exchange knowledge on epoxy and other thermoset materials. Furthermore, Alzchem targets the nutrition sector by marketing premium products for food and sports nutrition, dietary supplements, and cosmetics production. With a focus on innovation and quality, Alzchem positions itself as a key player in supporting developments in hydrogen-powered vehicles, lightweight construction, wind energy, and molecular diagnostics.

Summarized from source with an LLMView SourceSector: Industrials

Revenue Growth

Alzchem Group AG reported a total Group sales of EUR 286.3 million for the first half of 2024, marking a 3.3% increase compared to the previous year's figure of EUR 277.0 million. This growth was primarily driven by a 12.5% rise in sales within the Specialty Chemicals segment, which successfully offset an 11.8% decline in the Basics & Intermediates segment.

EBITDA Increase

In the first half of 2024, Alzchem Group AG achieved a significant increase in Group EBITDA, which grew by 41.2% to EUR 51.9 million. This growth was disproportionately strong in relation to sales, leading to an increase in the EBITDA margin from 13.3% to 18.1%.

Half-Year Profit

Alzchem Group AG's half-year result for the first half of 2024 climbed by 78.4%, reaching EUR 26.7 million compared to EUR 15.0 million in the previous year. This substantial increase reflects the company's enhanced earning power and successful business operations.

Cash Flow Improvement

The operating cash flow of Alzchem Group AG increased by EUR 24.0 million or 60.3% to EUR 63.8 million in the first half of 2024. Additionally, the free cash flow saw a significant rise of 64.5%, amounting to EUR 51.4 million, indicating strong financial health and effective working capital management.

Raised Earnings Forecast

Due to stronger growth in the first half of 2024 and a shift towards specialty chemicals, Alzchem Group AG's Management Board has raised its earnings forecasts for the full year 2024. Group EBITDA is now expected to exceed EUR 100 million, with the EBITDA margin projected to increase to 17.5%, up from the previously anticipated 15.8%.

Summarized from source with an LLMView Source

Key figures

240%1Y

322%3Y

502%5Y

Performance

41.6%1Y

35.2%3Y

36.6%5Y

Volatility